Role of the PPAR-γ system in normal and tumoral pituitary corticotropic cells and adrenal cells

Neuroendocrinology

Volumn 92, Issue SUPPL. 1, 2010, Pages 23-27

  Mannelli, Massimo ^a   Cantini, Giulia ^a   Poli, Giada ^a   Mangoni, Monica ^a   Nesi, Gabriella ^a   Canu, Letizia ^a   Rapizzi, Elena ^a   Borgogni, Elisa ^a   Ercolino, Tonino ^a   Piccini, Valentina ^a   Luconi, Michaela ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Adrenal cancer; Cushing's disease; Glitazones; Pituitary

Indexed keywords

BMI1 PROTEIN; CD31 ANTIGEN; GLITAZONE DERIVATIVE; METYRAPONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PROOPIOMELANOCORTIN; PROTEIN BCL 2; ROSIGLITAZONE; VASCULOTROPIN;

ADRENAL CANCER; ADRENAL CELL; ADRENALECTOMY; CONFERENCE PAPER; CORTICOSTERONE RELEASE; CORTICOTROPIN RELEASE; CUSHING DISEASE; HORMONAL REGULATION; HUMAN; HYPOPHYSIS ADENOMA; HYPOPHYSIS CELL; NONHUMAN; PRIORITY JOURNAL;

ADRENAL CORTEX; ADRENAL CORTEX NEOPLASMS; CORTICOTROPHS; HUMANS; PITUITARY ACTH HYPERSECRETION; PITUITARY GLAND; PITUITARY NEOPLASMS; PPAR GAMMA; THIAZOLIDINEDIONES;

EID: 77956523986     PISSN: 00283835     EISSN: None     Source Type: Journal    
DOI: 10.1159/000314312     Document Type: Conference Paper

References (20)

1. Lehrke M, Lazar MA: The many faces of PPARgamma. Cell 2005; 123: 993-999.
2. Panigrahy D, Huang S, Kieran MW, Kai-painen A: PPARgamma as a therapeutic target for tumor angiogenesis and metastasis. Cancer Biol Ther 2005; 4:687-693.
3. Heaney AP, Fernando M, Yong WH, Melmed S: Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas. Nat Med 2002; 8:1281-1287.
4. Alevizaki M, Philippou G, Zapanti L, Ale-vizaki CC, Anastasiou E, Mavrikakis M: Significant improvement of recurrent pituitary-dependent Cushing's syndrome after administration of a PPAR-gamma agonist (abstract). The Endocrine Society's 86th Annual Meeting, New Orleans, 2004, pp 2-453.
5. Hull SSA, Sherida n B, At kinson AB: Pre-op-erative medical therapy with rosiglitazone in two patients with newly diagnosed pituitary-dependent Cushing's syndrome. Clin Endo-crinol (Oxf) 2005; 62: 259-261.
6. Ambrosi B, Dall'Asta C, Cannavo S, Libe R, Vigo T, Epaminonda P, et al: Effects of chronic administration of PPAR-gamma li-gand rosiglitazone in Cushing's disease. Eur J Endocrinol 2004; 151: 17 3-17 8.
7. Suri D, Weiss RE: Effect of pioglitazone on adrenocorticotropic hormone and cortisol secretion in Cushing's disease. J Clin Endo-crinol Metab 2005; 90: 1340-1346.
8. Barbaro D, Lapi P, Orsini P, Pasquini C, Ciaccio S: Pioglitazone treatment in Cush-ing's disease (letter). J Endocrinol Invest 2005; 28:388-389.
9. Mullan KR, Leslie H, McCance DR, Sheridan B, Atkinson AB: The PPAR-gamma activator rosiglitazone fails to lower plasma ACTH levels in patients with Nelson's syndrome. Clin Endocrinol (Oxf) 2006; 64: 51 9-522.
10. Giraldi FP, Scaroni C, Arvat E, Martin M, Giordano R, Albiger N, et al: Effect of protracted treatment with rosiglitazone, a PPARgamma agonist, in patients with Cush-ing's disease. Clin Endocrinol (Oxf) 2006; 64: 219-224.
11. Munir A, Song F, Ince P, Walters SJ, Ross R, Newell-Price J: Ineffectiveness of rosigli-tazone therapy in Nelson's syndrome. J Clin Endocrinol Metab 2007; 92:1758-1763.
12. Ferr uzzi P, Cen i E, Ta rocch i M, Gr app one C, Milani S, Galli A, Fiorelli G, Serio M, Man-nelli M: Thiazolidinediones inhibit growth and invasiveness of the human adrenocorti-cal c a ncer cel l li ne H 295R. J Clin Endocrinol Metab 2005; 90: 1332-1339.
13. Betz MJ, Shapiro I, Fassnacht M, Hahner S, Reincke M, Beuschlein F, for the German and Austrian Adrenal Network: Peroxisome proliferator-activated receptor-gamma agonists suppress adrenocortical tumor cell proliferation and induce differentiation. J Clin Endocrinol Metab 2005; 90: 3886-3896.
14. Cantini G, Lombardi A, Piscitelli E, Poli G, Ceni E, Marchiani S, Ercolino T, Galli A, Se-rio M, Mannelli M, Luconi M: Rosiglitazone inhibits adrenocortical cancer cell proliferation by interfering with the IGF-IR intracel-lular signaling. PPAR Res 2008; 2008:904041.
15. Boulle N, Logíe A, Gicquel C, Perin L, Le Bouc Y: Increased levels of insulin-like growth factor II (IGF-II) and IGF-binding protein-2 are associated with malignancy in sporadic adrenocortical tumors. J Clin En-docrinol Metab 1998; 83:1713-1720.
16. Barlaskar FM, Spalding AC, Heaton JH, Kuick R, Kim AC, Thomas DG, Giordano TJ, Ben-Josef E, Hammer GD: Preclinical target i ng of t he t y pe I i nsu l i n-l i ke g row t h factor receptor in adrenocortical carcinoma. J Clin Endocrinol Metab 2009; 94: 204-212.
17. Luconi M, Mangoni M, Gelmini S, Poli G, Nesi G, Francalanci M, Pratesi N, Cantini G, Lombardi A, Pepi M, Ercolino T, Serio M, Orlando C, Mannelli M: Rosiglitazone impairs proliferation of human adrenocortical cancer: preclinical study in a xenograft mouse model. Endocr Relat Cancer 2010; 17: 169-177.
18. Read WL, Baggstrom MQ, Fracasso PM, Go-vindan R: A phase I study of bexarotene and rosiglitazone in patients with refractory cancers. Chemotherapy 2008; 54:236-241.
19. Reichle A, Bross K, Vogt T, Bataille F, Wild P, Berand A, Krause SW, Andreesen R: Piogli-tazone and rofecoxib combined with angio-statically scheduled trofosfamide in the treatment of far-advanced melanoma and soft tissue sarcoma. Cancer 2004; 101:2247-2256.
20. Luconi M, Cantini G, Serio M: Peroxisome proliferator-activated receptor gamma (PPAR-7): is genomic activity the only answer? Steroids 2009;75:585-594.